Limited coverage criteria – pamidronate

Last updated on March 20, 2025

 

Return to Special Authority drug list

Generic name

pamidronate 

Strength & form

all strengths and forms

Special Authority criteria

 

Approval period

Diagnosis indicating bone metastases associated with cancer (except breast cancer)

1 year

Practitioner exemptions

  • None

Special notes

  • None

Special Authority request form(s)